Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield

被引:1053
作者
Zolotukhin, S
Byrne, BJ
Mason, E
Zolotukhin, I
Potter, M
Chesnut, K
Summerford, C
Samulski, RJ
Muzyczka, N
机构
[1] Univ Florida, Coll Med, Gene Therapy Ctr, Gainesville, FL 32610 USA
[2] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA
[3] Univ Florida, Coll Med, Dept Pediat, Gainesville, FL 32610 USA
[4] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA
[5] Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC USA
关键词
adeno-associated virus; rAAV; gene therapy; vector production; vector purification;
D O I
10.1038/sj.gt.3300938
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Conventional methods for rAAV purification that are based on cesium chloride ultracentrifugation have often produced vector preparations of variable quality and resulted in significant loss of particle infectivity. We report here several novel purification strategies that involve the use of non-ionic iodixanol gradients followed by ion exchange or heparin affinity chromatography by either conventional or HPLC columns. These methods result in more than 50% recovery of rAAV from a crude lysate and routinely produce vector that is more than 99% pure. More importantly, the new purification procedures consistently produce rAAV stocks with particle-to-infectivity ratios of less than 100, which is significantly better than conventional methods. The new protocol increases the overall yield of infectious rAAV by at least 10-fold and allows for the complete purification of rAAV in 1 working day. Several of these methods should also be useful for large-scale production.
引用
收藏
页码:973 / 985
页数:13
相关论文
共 38 条
[1]   Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results [J].
Alexander, IE ;
Russell, DW ;
Miller, AD .
HUMAN GENE THERAPY, 1997, 8 (16) :1911-1920
[2]   High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors [J].
Chiorini, JA ;
Wendtner, CM ;
Urcelay, E ;
Safer, B ;
Hallek, M ;
Kotin, RM .
HUMAN GENE THERAPY, 1995, 6 (12) :1531-1541
[3]   CELL-LINES FOR THE PRODUCTION OF RECOMBINANT ADENOASSOCIATED VIRUS [J].
CLARK, KR ;
VOULGAROPOULOU, F ;
FRALEY, DM ;
JOHNSON, PR .
HUMAN GENE THERAPY, 1995, 6 (10) :1329-1341
[4]   Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle [J].
Clark, KR ;
Sferra, TJ ;
Johnson, PR .
HUMAN GENE THERAPY, 1997, 8 (06) :659-669
[5]   Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap [J].
Conway, JE ;
Zolotukhin, S ;
Muzyczka, N ;
Hayward, GS ;
Byrne, BJ .
JOURNAL OF VIROLOGY, 1997, 71 (11) :8780-8789
[6]   Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors [J].
Ferrari, FK ;
Samulski, T ;
Shenk, T ;
Samulski, RJ .
JOURNAL OF VIROLOGY, 1996, 70 (05) :3227-3234
[7]   Recombinant adeno-associated virus for muscle directed gene therapy [J].
Fisher, KJ ;
Jooss, K ;
Alston, J ;
Yang, YP ;
Haecker, SE ;
High, K ;
Pathak, R ;
Raper, SE ;
Wilson, JM .
NATURE MEDICINE, 1997, 3 (03) :306-312
[8]   Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis [J].
Fisher, KJ ;
Gao, GP ;
Weitzman, MD ;
DeMatteo, R ;
Burda, JF ;
Wilson, JM .
JOURNAL OF VIROLOGY, 1996, 70 (01) :520-532
[9]   Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus [J].
Flannery, JG ;
Zolotukhin, S ;
Vaquero, MI ;
LaVail, MM ;
Muzyczka, N ;
Hauswirth, WW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) :6916-6921
[10]   A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease [J].
Flotte, T ;
Carter, B ;
Conrad, C ;
Guggino, W ;
Reynolds, T ;
Rosenstein, B ;
Taylor, G ;
Walden, S ;
Wetzel, R .
HUMAN GENE THERAPY, 1996, 7 (09) :1145-1159